0001567619-20-006266.txt : 20200313 0001567619-20-006266.hdr.sgml : 20200313 20200313124913 ACCESSION NUMBER: 0001567619-20-006266 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200313 DATE AS OF CHANGE: 20200313 EFFECTIVENESS DATE: 20200313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elicio Therapeutics, Inc. CENTRAL INDEX KEY: 0001555192 IRS NUMBER: 452966790 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-362787 FILM NUMBER: 20711638 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 1400 WEST, SUITE 14303 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-209-0056 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 1400 WEST, SUITE 14303 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Vedantra Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20120730 D 1 primary_doc.xml X0708 D LIVE 0001555192 Elicio Therapeutics, Inc. ONE KENDALL SQUARE BUILDING 1400 WEST, SUITE 14303 CAMBRIDGE MA MASSACHUSETTS 02139 857-209-0056 DELAWARE None Vedantra Pharmaceuticals, Inc. Corporation true Robert Connelly c/o Elicio, One Kendall Sq. Bldg. Building 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Executive Officer Director Mr. Connelly is the Chief Executive Officer of the Issuer. Julian Adams c/o Elicio, One Kendall Sq. Bldg. 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Executive Officer Director Dr. Adams is the Executive Chairman of the Board of Directors of the Issuer. Daniel Geffken c/o Elicio, One Kendall Sq. Bldg. 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Executive Officer Director Mr. Geffken is the Chief Financial Officer of the Issuer. Isaac Kohlberg c/o Elicio, One Kendall Sq. Bldg. 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Director Robert Ruffolo c/o Elicio, One Kendall Sq. Bldg. 1400 West, Suite 14303 Cambridge MA MASSACHUSETTS 02139 Director Biotechnology Decline to Disclose 06b false 2020-02-27 false true true Common Stock; Series B Preferred Stock false 0 None None Maxim Group LLC 120708 405 Lexington Avenue New York NY NEW YORK 10174 All States false 8411801 8411801 0 false 108 841180 0 The persons named in Item 12 received a 10% commission consisting of cash and warrants. 0 false Elicio Therapeutics, Inc. /s/ Robert Connelly Robert Connelly Chief Executive Officer of the Issuer 2020-03-13